IXICO plc Contract win for new stroke study (7921W)
April 28 2021 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 7921W
IXICO plc
28 April 2021
IXICO plc
("IXICO" or the "Company")
Contract win for new stroke study
New therapeutic area, broadening IXICO's neurological
footprint
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , announces that it has executed a
contract to provide neuroimaging services for a new clinical trial
for acute ischemic stroke with its largest pharma client.
The contract win reflects a further broadening of IXICO's
neurological footprint into a new therapeutic area with this client
and demonstrates that the Company continues to build momentum in
its growth strategy of further diversification into new therapeutic
areas. Ischemic stroke is caused by a blockage cutting off the
blood supply to the brain. This is the most common form of stroke
and accounts for approximately 85% of cases. The new Phase II acute
ischemic stroke trial, will be conducted across 50 sites in North
America and Europe and is worth in excess of US$0.5m over 35
months.
Lammert Albers, Chief Commercial Officer of IXICO, commented:
"We are delighted to be awarded this new study by our existing
pharma client. Having singularly focused on neurological disorders
since our inception in 2004, IXICO has a long and established
history of delivering advanced neuroimaging solutions to the
biopharmaceutical sponsors. This new contract demonstrates our
continually expanding footprint and deepening expertise within
IXICO's proven specialist domain. "
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicoNews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTSESESWEFSEDL
(END) Dow Jones Newswires
April 28, 2021 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024